Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. - Wikidata - wikimedia - TriplyDB

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

http://www.wikidata.org/entity/Q35116581

about

A Blueprint for HIV Vaccine Discovery Resolve, revise, and relax: the 3 Rs of B cell repertoire adjustment HIV-1 neutralizing antibodies: understanding nature's pathways HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design Virological features associated with the development of broadly neutralizing antibodies to HIV-1 Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41 Structural Definition of an Antibody-Dependent Cellular Cytotoxicity Response Implicated in Reduced Risk for HIV-1 Infection Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic Antibody Autoreactivity and Exceptional CDR Plasticity (but Not Unusual Polyspecificity) Hinder Elicitation of the Anti-HIV Antibody 4E10 Progress in HIV-1 vaccine development.Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Stabilized HIV-1 envelope glycoprotein trimers for vaccine use.Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion.Immunopathogenesis of simian immunodeficiency virus infection in nonhuman primates Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen.Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination.Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study Isolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrum Vaccines that stimulate T cell immunity to HIV-1: the next step 9G4+ antibodies isolated from HIV-infected patients neutralize HIV-1 and have distinct autoreactivity profiles.Fusion of ubiquitin to HIV gag impairs human monocyte-derived dendritic cell maturation and reduces ability to induce gag T cell responses.HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.A broad range of mutations in HIV-1 neutralizing human monoclonal antibodies specific for V2, V3, and the CD4 binding site.A systematic review of syphilis serological treatment outcomes in HIV-infected and HIV-uninfected persons: rethinking the significance of serological non-responsiveness and the serofast state after therapy.Exceptional Antibodies Produced by Successive Immunizations.Altered Ig hypermutation pattern and frequency in complementary mouse models of DNA polymerase ζ activity.Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors.Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape.Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design Neutralizing antibodies to HIV-1 induced by immunization.Role of IL-21 and IL-21 receptor on B cells in HIV infection.Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1 Anti-HIV B Cell lines as candidate vaccine biosensors.Lessons learned from HIV-1 vaccine trials: new priorities and directions

P2860

Q26829865-47E04397-01D5-4066-BAEF-CE6138C6BAD7 Q26852927-26D22032-08C2-4E88-B546-520801C74D31 Q27000480-1817B135-42B0-4781-98D0-FEC7D6838151 Q27022055-A6B33C78-05FF-4498-9E92-B0AF926F1880 Q27025177-FBABCB7E-8F93-44A1-9286-DD5BE315BDB9 Q27312171-8D2156BA-26FB-4CBF-AA63-C4179AF5B686 Q27640572-423A3558-0F92-42A0-8637-CEE4F36B9491 Q27644415-B3177FFE-7E07-4052-91DF-14C281FE6BBF Q27680125-ABE041C3-A9DD-4811-806D-E99A57B1550E Q27693849-1C1EA51E-E954-4527-9749-FD74163303F2 Q28602877-6D077764-7BA8-4529-9C86-18AC37D4C832 Q28730532-348CB21D-6B20-4550-8B98-B087F4163E82 Q30234773-E796077A-2AB9-46FC-AE1F-7196FE74D5BF Q30490942-2AF857E0-1D89-4EF4-8A4D-47AA844CA95F Q31151010-1367112C-4433-4F8C-B849-9A1C3E1724F2 Q33355730-EAB9E3BD-8262-42E0-A00C-C2FB3E8221CE Q33620546-8D137A86-2F26-4862-BE83-1FDA8F291797 Q33702217-4B595240-A55C-4D68-B104-E91D6526710C Q33922778-96C2D1F7-4EB9-4EB5-9DA4-0E898C5752E8 Q34022578-55916900-C1AB-4BAD-8A70-5F80076927FE Q34177732-4B3EB5EF-2386-4481-95D0-AE488467E167 Q34273373-56D46291-5FC5-4311-8508-8A01C5F7F926 Q34280115-CE873110-065C-4FFE-82AA-37F06790A367 Q35073079-BDAE72B0-C519-4791-B39E-57EE4344DFF6 Q35081119-A17FE89F-D157-402E-8493-2AC5AC729F81 Q35088691-E3997016-48DF-4183-8DB7-394E7FCE294C Q35172770-F390BE08-9AB9-4923-80D0-9449D4C73848 Q35706462-60D016B0-DAE3-4C40-AAF3-D1E53562A5B6 Q35825170-1A5AE1B8-F8EC-447B-9F46-9DC4FA2ADED0 Q35862420-A304D352-3F82-4034-BD40-59135FC00126 Q35980902-458C99A8-004D-462B-A2A4-76BEDE8DFD99 Q36010933-6F992440-CDCA-43E0-95B7-EE292C71580E Q36246403-6DC70A78-B875-4065-AD24-E42F9D99F62F Q36447540-4AC355DD-FE46-43D9-8DBA-C24305ADF085 Q36603515-60B7F320-5B2E-4095-99BC-F0CF85B7464A Q36670538-11655B37-9FE0-4DD5-AD13-487CF6F9A957 Q36759963-DA5FBB6B-74C2-4B6A-84E5-3A04834D714A Q36760169-ABF6C27C-C5EF-4E41-B003-FD539583D32D Q36766704-300FC338-3C02-4AD5-B8F1-02B2217EAAC0 Q36839817-B944D440-8B73-477E-8FFA-EDEFDF7A0420

P2860

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

http://www.wikidata.org/entity/Q35116581

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

@ast

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

@en

type

label

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

@ast

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

@en

prefLabel

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

@ast

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

@en

P1433

Q35116581-12B6ACF5-A5E4-4304-855C-9C50AE021B0B

P1476

Q35116581-3C4172E9-981E-4A82-9340-B7748738D77A

P2093

Q35116581-6B991ADC-AE9C-48A2-A87D-37B3DA4F4C18

Q35116581-6D7BF2A9-FD8D-4547-9B4D-B21875496273

P2860

Q35116581-01366F21-1E10-4B1E-88D8-E75A5985DAF8

Q35116581-01983DAC-C136-4A1B-8F17-F1D92036A9A4

Q35116581-033F4010-CA23-4A88-8EFB-3D2FED27C616

Q35116581-06872659-0173-476D-B8A9-03290D9CA122

Q35116581-0694FCB2-4EC8-46D3-9B5D-ABCBDD0F64DC

Q35116581-16C5E382-6AE0-4DDA-AB2C-B8C0DA93720F

Q35116581-188545BF-8D01-4FC7-B29F-E61BFB846423

Q35116581-19CE3F25-9240-49C0-AF47-5A748BF667E5

Q35116581-1B94CAF7-3F99-4B35-8CB3-922C35472C5D

Q35116581-1E9C7396-3CF5-42F1-9690-4EA8943E5F62

P304

Q35116581-EE2DB772-039B-4A90-81D3-33E7E0FE80DB

P31

Q35116581-5DB97C90-AD18-4B8F-93F8-D25848820F17

P356

Q35116581-CAE60007-5C80-45F5-ACA0-870C95B0812A

P433

Q35116581-380A56D2-4337-45BD-812F-88500338D866

P478

Q35116581-04FA4281-F954-4011-BF14-86FD7F76AC86

P50

Q35116581-950AC4D0-71E2-45DC-B8A0-7EC15550BFBA

Q35116581-EAF0BA3A-AC4A-4F59-AF1D-0C83A4E6CF44

P577

Q35116581-6F3297AC-E34A-4138-817B-AC335F272A41

P5875

Q35116581-3D1627E1-40E1-420B-A576-E09C7F7AC19C

P698

Q35116581-43ACCD51-B58C-4F0A-A7D8-848CAD69832A

P921

Q35116581-E1A4AEF1-058C-450E-8BCF-61813725ACF0

P932

Q35116581-78FE7D77-9586-48AE-A701-482E4A3BB963

P356

J.COI.2011.04.003

P1433

Current Opinion in Immunology

P1476

Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

@en

P2093

Laurent Verkoczy

http://www.w3.org/2001/XMLSchema#string

M Anthony Moody

http://www.w3.org/2001/XMLSchema#string

P2860

Few and far between: how HIV may be evading antibody avidity

Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1

A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies

HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane

Structure of a clade C HIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

Marginal-zone B cells

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

B-cell tolerance checkpoints in health and autoimmunity

Antibody neutralization and escape by HIV-1

P304

383-390

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.COI.2011.04.003

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51081564

http://www.w3.org/2001/XMLSchema#string

P698

21524897

http://www.w3.org/2001/XMLSchema#string

P921

P932

3139952

http://www.w3.org/2001/XMLSchema#string